Population Pharmacokinetics and Exposure-Efficacy and Safety Analyses of Alectinib in Crizotinib-Progressed or Intolerant Population

Hsu Joy C.; Carnac Ronan; Bogman Katrijn; Martin-Facklam Meret; Guerini Elena; Balas Bogdana; Zeaiter Ali; Phipps Alex; Morcos Peter N.; Frey Nicolas

首页> 外文期刊>Journal of pharmacokinetics and pharmacodynamics >Population Pharmacokinetics and Exposure-Efficacy and Safety Analyses of Alectinib in Crizotinib-Progressed or Intolerant Population

【24h】

Population Pharmacokinetics and Exposure-Efficacy and Safety Analyses of Alectinib in Crizotinib-Progressed or Intolerant Population

机译：依唑替尼治疗或不耐受的人群中伊乐替尼的群体药代动力学和暴露效果及安全性分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of pharmacokinetics and pharmacodynamics》 |2016年第suppla期|共1页
作者
Hsu Joy C.; Carnac Ronan; Bogman Katrijn; Martin-Facklam Meret; Guerini Elena; Balas Bogdana; Zeaiter Ali; Phipps Alex; Morcos Peter N.; Frey Nicolas;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Population Pharmacokinetics and Exposure-Efficacy and Safety Analyses of Alectinib in Crizotinib-Progressed or Intolerant Population [J] . Hsu Joy C., Carnac Ronan, Bogman Katrijn, Journal of pharmacokinetics and pharmacodynamics . 2016,第Suppla期

机译：依唑替尼治疗或不耐受的人群中伊乐替尼的群体药代动力学和暴露效果及安全性分析
2. Population Pharmacokinetic and Exposure-Efficacy/Safety Analyses for Selection of Optimal Dose Regimen of Tocilizumab in Patients With Giant Cell Arteritis (GCA) [J] . Gibiansky Leonid, Gibiansky Ekaterina, Frey Nicolas, Journal of pharmacokinetics and pharmacodynamics . 2017,第Suppla期

机译：人口药代动力学和曝光疗效/安全分析，用于选择巨型细胞动脉炎患者幼稚毒素的最佳剂量方案（GCA）
3. POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES CONFIRM THE ALECTINIB 600 MG BID DOSE IN THE GLOBAL ALK INHIBITOR-NAIVE POPULATION. [J] . Hsu J. C., Jaminion F., Guerini E., Clinical Pharmacology and Therapeutics . 2018,第Suppla1期

机译：人口药代动力学和暴露 - 反应分析证实全球alk抑制剂 - 幼稚群体中的邻接600mg BID剂量。
4. In silico assessment of nifedipine effects on human heart cells: Pharmacokinetic-pharmacodynamic analyses at the population level [C] . Mitra Abbasi, Sebastian Polak Computing in Cardiology Conference . 2017

机译：硝苯地平对人体心脏细胞影响的计算机评估：人群水平的药代动力学-药效学分析
5. Factors that are important in determining the statistical significance of covariates during population pharmacokinetic analyses. [D] . Knebel, William. 2000

机译：在人群药代动力学分析过程中确定协变量的统计显着性的重要因素。
6. Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden [O] . Colby S. Shemesh, Phyllis Chan, Fatema A. Legrand, 2020

机译：肿瘤大肿瘤突变负担患者含毒素癌的药代动力学和暴露 - 安全性和效率分析
7. Population-Based Pharmacokinetic and Exposure-Efficacy Analyses of Peginterferon Beta-1a in Patients With Relapsing Multiple Sclerosis [O] . Xiao Hu, Yaming Hang, Yue Cui, 2017

机译：复发多发性硬化症患者Peginterferonβ-1a的群体的药代动力学和曝光效果分析

Population Pharmacokinetics and Exposure-Efficacy and Safety Analyses of Alectinib in Crizotinib-Progressed or Intolerant Population

著录项

相似文献

相关主题

期刊订阅